Frontlight ResearchEarly access
Taking peopleNo phase
Platelet-Directed Whole Blood Transfusion Strategy for Malaria
Key facts
- Who runs it
- Johns Hopkins Bloomberg School of Public Health
- Where
- Baltimore, United StatesSee the siteAlso in 1 other country, 1 site
- Trial code
- Status
- Recruiting
- People taking part
- 132 people, planned
- Started
- 24 Feb 2024
- Expected to end
- 31 May 2028
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Whole blood transfusion
- Record updated
- 11 September 2026
Who can take part
- Age
- 1 month to 59 months
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (12)Hide the full registry criteria
Who can take part
- Age <5 years
- Platelet count ≤100,000/uL
- Hemoglobin >5 and ≤11 g/dL
- P. falciparum parasitemia ≥500 parasites/uL
- Diagnosis of severe malaria meeting World Health Organization (WHO) criteria
- Ability and willingness of the legal guardian to comply with study protocol for the duration of the study
- Residence within health clinic catchment area
- Signed informed consent obtained from the parent or legal guardian of the participant
Who cannot take part
- Presence of any other condition or abnormality which, in the opinion of the investigator, would compromise the safety of the participant or the quality of the data
- Residence in foster care or children otherwise under government supervision
- Residence outside the hospital catchment area, or plan to leave the area
- Any contraindication to whole blood transfusion
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Severe malaria or thrombocytopenia
Where in United States
Also in 1 other country, 1 site
- Johns Hopkins Bloomberg School of Public HealthBaltimore, United StatesContact: Matthew M Ippolito, MD PhDNo longer taking part
About the trial
What the trial wants to find out
Open-label randomized controlled trial to test the effectiveness of whole blood transfusion for improving survival in children with severe malaria complicated by thrombocytopenia.
The 2 groups in the trial
- Whole blood transfusionTreatment being tested
Whole blood transfusion x1 (20 mL/kg)
- ControlNo study treatment, for comparison
Standard-of-care
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
Download the PDF
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical and Translational Investigations of Severe Malaria Pathophysiology [Parent Study Protocol]
- Criteria questions
- Built from NCT05711485, who can take part
- Record updated
- 11 September 2026